On October 11, 2025, iLABMED has been accepted for inclusion in the Chinese Science Citation Database (CSCD), as announced in the 2025–2026 source journal list released by the National Science Library of the Chinese Academy of Sciences.
This achievement reflects a significant recognition of the journal's academic quality, editorial standards, and growing influence within China's authoritative evaluation framework. It stands as a testment to iLABMED's unwavering commitment to scholarly excellence and the dedicated efforts of its editorial board, reviewers, and authors.
Moving forward, iLABMED will continue to adhere to its founding mission of upholding "high quality, high standards, and global reach." It will continue to champion interdisciplinary research in laboratory medicine and related fields to better serve the scientific community.
The editorial team extends sincere gratitude to all authors, readers, and experts for their continued support. Researchers worldwide are invited to submit their papers and cite articles published in iLABMED to help further elevate its impact on the scientific landscape.
About the Journal
iLABMED is a peer-reviewed, open-access English journal that publishes high-quality research across all areas of laboratory medicine and related disciplines. It is academically supported by Shenzhen Third People's Hospital and published by Tsinghua University Press, with international distribution by Wiley.
The journal is organized into 14 dedicated academic sections to ensure focused and expert handling of submissions in each specialty. These include bio-informatics, cell biology, clinical microbiology, clinical biochemistry, clinical hematology and body fluid analysis, clinical immunology, endocrinology, intelligent medicine, molecular pathology, cancer bio-therapy, preventive medicine, transfusion medicine, neuroscience, molecular genetics, and more.
iLABMED was selected as a high-starting-point new journal under the “China STEM Journal Excellence Action Plan” in September 2023. It is already indexed in the DOAJ and other international databases and has now been included in the 2025–2026 CSCD.
Editorial Board Members:
· Honorary Editors-in-Chief:
Academician DONG Jiahuan (Chinese Academy of Engineering)
Academician MA Guanghui (Chinese Academy of Sciences)
· Editor-in-Chief:
LU Hongzhou, President of Shenzhen Third People's Hospital, Fellow of the American Academy of Microbiology
· Co-Editors-in-Chief:
Professor TANG Yiyi, Chongqing Medical University, Academic Dean of the School of Public Health; Fellow of the American Academy of Microbiology
Professor Asakawa Tetsuya, Institute of Neurology, Shenzhen Third People's Hospital
Professor Eric von Hofe, AffyImmune Therapeutics
· Executive Editor-in-Chief:
Professor LIU Jie, Seventh Medical Center of the Chinese PLA General Hospital
Types of Articles:
Original Articles, Reviews, Commentaries, Short Communications, Case Reports, Clinical Guidelines, News and Views, Letters to the Editor, and Editorials.
Services & Policies:
No Article Processing Charges until 2026
Free language editing for accepted manuscripts
Free-format submission to simplify the submission process
Visit the Journal at:
https://www.sciopen.com/journal/2834-443X
https://onlinelibrary.wiley.com/journal/28344448
Submission Link:
https://wiley.atyponrex.com/journal/ILA2
Contact the editorial team:
ilabmed@tup.tsinghua.edu.cn
